Intravenous immune globulin has been used in the treatment of primary and secondary antibody deficiencies for more than 25 years. It is a safe preparation with no long-term side effects. Intravenous immune globulin was first demonstrated to be effective in an autoimmune disorder — idiopathic thrombocytopenic purpura — two decades ago. Since then, it has been established to be efficacious in the treatment of the Guillain–Barré syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, corticosteroid-resistant dermatomyositis, and Kawasaki's syndrome and in the prevention of graft-versus-host disease in recipients of allogeneic bone marrow transplants. Benefits have been reported in many other autoimmune . . .